Phase II Trial on Adaptive Radiation Planning in NSCLC to Reduce Toxicity
A phase II trial is investigating adaptive radiation planning to minimize side effects in patients with stage II-IV non-small cell lung cancer.
Indication
Clinical and regulatory intelligence for Non-small Cell Lung Cancer with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Cancer-associated fibroblasts (CAFs) promote the expression of CD39 and CD73 on T cells, leading to increased adenosine synthesis, which may facilitate tumor immune evasion.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.